Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the scheduled date for BioSyent Inc.'s Q4 and full year 2020 earnings release. It states the company will report financial results on March 17, 2021, and mentions a presentation will be available on the same date. The document itself does not contain any financial results or substantive financial data, only an announcement of the upcoming earnings release. According to the 'MENU VS MEAL' rule, such announcements are classified as Earnings Release (ER) if they contain key highlights, but this document only announces the date and availability of the report, not the results themselves. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about the timing of the earnings release, not the earnings release itself.
2021-03-11 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the launch of a new pharmaceutical product, Combogesic, by BioSyent Inc. It contains no financial data, regulatory filings, or detailed financial reports. It is a corporate news announcement about a product launch, not a financial report, management change, or regulatory filing. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-12-16 English
News release - English.pdf
Transaction in Own Shares Classification · 95% confidence The document is a press release announcing the renewal of a Normal Course Issuer Bid (NCIB) by BioSyent Inc. It details the company's intention to repurchase its own shares, including the number of shares, the period of the bid, and the rationale behind the buyback. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is not a report but an announcement of a capital activity related to share repurchases. According to the filing definitions, announcements regarding share repurchases or sales of own shares fall under the category 'Transaction in Own Shares' (POS). The document length is 4340 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is POS with high confidence.
2020-12-11 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'BioSyent Inc. Management’s Discussion and Analysis' and covers the three and nine months ended September 30, 2020 and 2019. It contains detailed sections on financial results, operations, strategy, accounting policies, and forward-looking statements. It references interim unaudited condensed consolidated financial statements prepared under IAS 34 (Interim Financial Reporting). The content includes detailed financial performance measures, business overview, and management commentary. This matches the characteristics of a Management Discussion and Analysis (MD&A) report, which provides management's detailed explanation of financial results, business trends, and outlook for a period shorter than a full fiscal year. Therefore, the document should be classified as a Management Reports (MDA) filing type.
2020-11-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2020-11-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2020-11-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.